an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
Published 5 years ago • 455 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
2:12
erdafitinib: one more tool for bladder cancer
-
1:47
the future role of erdafitinib in advanced urothelial carcinoma
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
5:14
erdafitinib demonstrates efficacy in intermediate-risk nmibc with fgfr alterations
-
3:37
phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
1:27
thor-2 cohort 3 interim analysis: erdafitinib in intermediate-risk nmibc with fgfr3/2 alterations
-
4:43
erdafitinib for fgfr-mutated urothelial carcinoma
-
3:26
blc2001: erdafitinib for muc
-
2:52
fgfri treatment-emergent aes in urothelial cancer
-
2:53
effect of fgfr status on checkpoint inhibitor response in bladder cancer
-
3:06
urothelial carcinoma trial updates from asco 2018
-
11:42
fgfr inhibitors in bladder cancer: testing, screening and highlights from asco 2020
-
11:35
update on first biomarker-directed trial of non-muscle-invasive bladder cancer
-
2:02
the evolving treatment landscape for urothelial cancer